According to the research report titled ‘Europe In-vitro Colorectal Cancer Screening Tests Market Size By Test Type Industry Analysis Report, Regional Outlook Potential, Competitive Market Share & Forecast, 2020 - 2026‘, available with Market Study Report, Europe in-vitro colorectal cancer screening tests market is anticipated to exceed USD 515 billion by the year 2026.
 

Technological developments and favorable reimbursement policies are the major factors expected to drive the growth of Europe in-vitro colorectal cancer screening tests market during the forecast period. For example, complete reimbursement insurance is available for screening colonoscopy for patients over  55 years of age in Germany.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2609872/
 

Furthermore, launch of genetic testing has enhanced screening accuracy for colorectal cancer, thereby contributing to the market growth. Initiatives by European Union such as national and transnational population-wide screening programs for healthcare policy are stimulating Europe in-vitro colorectal cancer screening tests industry outlook.
 

Based on test type, Fecal Occult Blood Test (FOBT) segment of Europe in-vitro colorectal cancer screening tests marketplace accounted for USD 312 million in 2019. The test is cost effective and easy to use. Furthermore, the launch of Immuno-FOBT for detection of advanced adenomas and colorectal cancer has resulted in better sensitivity and specificity of stool-based screening.
 

With regards to regional overview, Germany in-vitro colorectal cancer screening tests market is estimated to amass substantial gains during the forecast period, mainly due to rising utilization of screening test for early detection of bowel cancer along with evolving lifestyle, and changing food consumption patterns in the region.
 

Meanwhile, Italy in-vitro colorectal cancer screening tests industry is also poised to grow significantly with 6.1% CAGR over 2020-2027, owing to enhancements in diagnostic treatments & procedures and rising risk of cancer-related illnesses. Besides, surging geriatric population leading to increase in health care expenditure is contributing towards the market revenues in Italy.
 

Key players operating in Europe in-vitro colorectal cancer screening tests industry sphere are Abbott Laboratories, Sysmex Corporation, Siemens Healthineers, EMD Millipore, Randox Laboratories Ltd., Coulter Diagnostics, Qiagen N.V., Beckman Coulter Inc., Quest Diagnostics, R-Biopharm AG, Kyowa Kirin Co. Ltd. (Kyowa Medex Co., Ltd.), Roche Molecular Systems Inc., Novigenix SA, and Epigenomics Inc.